TMFEBCapital

Todd Campbell

TMFEBCapital’s Activity

Today

NL

Article

EBCapitalMarkets published an article 3 hours ago

Healthcare IT Sparks Sales At Quality Systems, But Profit Drops

Quality Systems sales headed higher last quarter; however, competitive pressure and higher R&D spending weighed down profit.

Yesterday

NL

Article

EBCapitalMarkets published an article 3:22 PM

1 Bright Spot in 3D Systems Corporation's Dismal Quarter

3D Systems warned investors of sagging sales, but said its healthcare business remains strong.

NL

Article

EBCapitalMarkets published an article 11:45 AM

Why Biogen Idec Stock Shares Are Getting Pummeled Today

Biogen Idec shares tumbled more than 10% today on news that a Tecfidera patient was diagnosed with a rare brain disease.

Rule Breakers article.

EBCapitalMarkets published an update. 9:23 AM

Tue Oct 21

NL

Article

EBCapitalMarkets published an article 9:11 PM

Cubist Pharmaceuticals Inc's Momentum Builds As Anti-Infection Product Line Grows

Cubist reported better than expected third quarter results this week.

Mon Oct 20

NL

Article

EBCapitalMarkets published an article 6:21 PM

3 Biotech Stocks With Humongous Short Interest

These three biotech companies may benefit if short sellers reverse course.

Fri Oct 17

NL

Article

EBCapitalMarkets published an article 12:53 PM

3 Top Dividend Stocks for the Rest of 2014

If markets find their footing, these three dividend stocks may reward investors.

Thu Oct 16

Stock Advisor article.

EBCapitalMarkets published an update. 1:25 PM

NL

Article

EBCapitalMarkets published an article 9:14 AM

Medicaid Juices UnitedHealth Group Inc.'s Quarter

UnitedHealth Group reported sales and profit grew this past year thanks to rising Medicare and Medicaid enrollment.

Wed Oct 15

NL

Article

EBCapitalMarkets published an article 11:51 AM

3 Drugs Critical to Johnson & Johnson's Future

Johnson & Johnson faces new threats to top selling drugs this year, but these three drugs may blunt the risk.

Tue Oct 14

NL

Article

EBCapitalMarkets published an article 4:06 PM

What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock

Slipping sales for Johnson & Johnson's hepatitis C drug Olysio may give Gilead investors reason for pause.

NL

Article

EBCapitalMarkets published an article 1:55 PM

Will Sagging Scripts Dent Gilead Sciences, Inc. Earnings?

Fewer prescriptions for Gilead's Sovaldi may weigh down Gilead's results for the third quarter.

NL

Article

EBCapitalMarkets published an article 12:21 PM

Should Gilead Sciences, inc. Fear Incoming Competition?

A price war might be coming in hepatitis C treatments, but should Gilead be worried about AbbVie and Bristol-Myers Squibb?

NL

Article

EBCapitalMarkets published an article 10:17 AM

3 Small-Cap Biotech Stocks to Buy if the Market Crashes

Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.

Mon Oct 13

NL

Article

EBCapitalMarkets published an article 5:05 PM

3 Dividend Stocks to Buy If the Market Crashes

Three dividend-paying healthcare stocks that may be worth buying as the market slips.

Sun Oct 12

NL

Article

EBCapitalMarkets published an article 11:24 AM

Baby Boomers Face Risks Co-Signing Student Loans

Grandparents should think twice before offering their signatures.

Sat Oct 11

NL

Article

EBCapitalMarkets published an article 12:37 PM

Gilead Sciences, inc. Stock's Green Light Sparks Offensive

Gilead Sciences will need to convince healthcare payers to prescribe its new hepatitis C drug Harvoni.

Fri Oct 10

NL

Article

EBCapitalMarkets published an article 5:48 PM

1 Obamacare Statistic Worth Knowing

The level of uninsured people continues to decline ahead of the second open-enrollment period.

NL

Article

EBCapitalMarkets published an article 2:08 PM

Warren Buffett Tells You How to Handle a Market Crash

A walk through Warren Buffett's annual letters to shareholders reveals some gems for profiting from rough markets.

Thu Oct 9

NL

Article

EBCapitalMarkets published an article 12:48 PM

Can Arrowhead Research Corp. Stock Recover from Its Horrendous Drop?

Arrowhead's shares fell more than 40% following the company's presentation on ARC-520 as a treatment for hepatitis B.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 27.54
Player Rank 54394 out of 75062
Score -178.70
Score Change Today -14.72
Accuracy 38.24%
Active Picks 34
Total Picks 34
Best Pick GILD (+68.08)
Worst Pick WFM (-46.44)
Average Score per Pick -5.26
Charms Earned 5
Highest Rated Favorite No Favorites Selected
Go to TMFEBCapital’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show TMFEBCapital’s 10 Latest Posts